AIM ImmunoTech To Test Ampligen In Post-COVID-19 Cognitive Dysfunction
AIM ImmunoTech Inc (NYSE: AIM) has submitted a Pre-Investigational New Drug application (Pre-IND) to the FDA for a Phase 2 study of…
AIM ImmunoTech Submits Pre-IND Application To FDA For Phase 2 Clinical Study Of Ampligen As Potential Infusion Therapy For Post-COVID-19 Cognitive Dysfunction
AIM ImmunoTech Inc. (NYSE:AIM) today announced that is has submitted a Pre-Investigational New Drug application (Pre-IND) to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical study of Ampligen as a
AIM ImmunoTech Reports Filed Provisional Patent Application For Use Of Ampligen As Both Intranasal, IV Therapy For Post-COVID-19 Cognitive Dystfunction
AIM ImmunoTech Inc. (NYSE:AIM) today provided an update on the company’s efforts to develop its drug Ampligen as a potential intranasal therapeutic for COVID-19, including the announcement of a new provisional
AIM ImmunoTech Q2 EPS $(0.12) Misses $(0.08) Estimate, Sales $23.00K Miss $350.00K Estimate
AIM ImmunoTech (AMEX:AIM) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.08) by 50 percent. This is a 9.09 percent decrease over losses of $(0.11) per share from the
Earnings Scheduled For August 13, 2021
Companies Reporting Before The Bell
• Jaguar Health (NASDAQ:JAGX) is expected to report quarterly loss at $0.03 per share on revenue of $7.28 million.
AIM ImmunoTech Reports Phase 2a Human Challenge Trial To Test Its Drug Ampligen As Intranasal Antiviral Prophylactic Therapy
AIM ImmunoTech Inc. (NYSE:AIM) today announced that it has signed a contract to sponsor a Phase 2a Human Challenge Trial (HCT) to test the company’s drug Ampligen as a potential intranasal antiviral therapy using a
AIM ImmunoTech Says Completes All Treatments In Phase 1 Human Safety Study Of Intranasal Administration Of Ampligen
AIM ImmunoTech Inc. (NYSE:AIM) today announced that all subjects have completed treatment in the Company's Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as a potential
AIM ImmunoTech Highlights Ampligen Featured in Peer-Reviewed Journal Cancers As A Potential Therapy For Cancer Patients With SARS-CoV-2
AIM ImmunoTech Inc. (NYSE:AIM) today announced that its drug Ampligen has been featured in a publication containing state-of-the-art methodologies in the peer-reviewed medical journal Cancers as a potential
Earnings Scheduled For May 14, 2021
Companies Reporting Before The Bell
• Sogou (NYSE:SOGO) is projected to report earnings for its first quarter.
• Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its first quarter.